|
1
|
Kawahara N, Kobayashi H, Maehana T, Iwai K, Yamada Y, Kawaguchi R, Takahama J, Marugami N, Nishi H, Sakai Y, Takano H, Seki T, Yokosu K, Hirata Y, Yoshida K, Ujihira T, Kimura F. MR Relaxometry for Discriminating Malignant Ovarian Cystic Tumors: A Prospective Multicenter Cohort Study. Diagnostics (Basel) 2024; 14:1069. [PMID: 38893596 PMCID: PMC11172376 DOI: 10.3390/diagnostics14111069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2024] [Revised: 05/18/2024] [Accepted: 05/19/2024] [Indexed: 06/21/2024] Open
Abstract
BACKGROUND Endometriosis-associated ovarian cancer (EAOC) is a well-known type of cancer that arises from ovarian endometrioma (OE). OE contains iron-rich fluid in its cysts due to repeated hemorrhages in the ovaries. However, distinguishing between benign and malignant tumors can be challenging. We conducted a retrospective study on magnetic resonance (MR) relaxometry of cyst fluid to distinguish EAOC from OE and reported that this method showed good accuracy. The purpose of this study is to evaluate the accuracy of a non-invasive method in re-evaluating pre-surgical diagnosis of malignancy by a prospective multicenter cohort study. METHODS After the standard diagnosis process, the R2 values were obtained using a 3T system. Data on the patients were then collected through the Case Report Form (CRF). Between December 2018 and March 2023, six hospitals enrolled 109 patients. Out of these, 81 patients met the criteria required for the study. RESULTS The R2 values calculated using MR relaxometry showed good discriminating ability with a cut-off of 15.74 (sensitivity 80.6%, specificity 75.0%, AUC = 0.750, p < 0.001) when considering atypical or borderline tumors as EAOC. When atypical and borderline cases were grouped as OE, EAOC could be distinguished with a cut-off of 16.87 (sensitivity 87.0%, specificity 61.1%). CONCLUSIONS MR relaxometry has proven to be an effective tool for discriminating EAOC from OE. Regular use of this method is expected to provide significant insights for clinical practice.
Collapse
Affiliation(s)
- Naoki Kawahara
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara 634-8522, Japan; (H.K.); (T.M.); (K.I.); (Y.Y.); (R.K.); (F.K.)
| | - Hiroshi Kobayashi
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara 634-8522, Japan; (H.K.); (T.M.); (K.I.); (Y.Y.); (R.K.); (F.K.)
- Department of Gynecology and Reproductive Medicine, Ms. Clinic MayOne, 871-1 Shijo-Cho, Kashihara 634-0813, Japan
| | - Tomoka Maehana
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara 634-8522, Japan; (H.K.); (T.M.); (K.I.); (Y.Y.); (R.K.); (F.K.)
| | - Kana Iwai
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara 634-8522, Japan; (H.K.); (T.M.); (K.I.); (Y.Y.); (R.K.); (F.K.)
| | - Yuki Yamada
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara 634-8522, Japan; (H.K.); (T.M.); (K.I.); (Y.Y.); (R.K.); (F.K.)
| | - Ryuji Kawaguchi
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara 634-8522, Japan; (H.K.); (T.M.); (K.I.); (Y.Y.); (R.K.); (F.K.)
| | - Junko Takahama
- Department of Radiology, Higashiosaka City Medical Center, Higashiosaka 578-8588, Japan;
| | - Nagaaki Marugami
- Department of Radiology and Nuclear Medicine, Nara Medical University, Kashihara 634-8522, Japan;
| | - Hirotaka Nishi
- Department of Obstetrics and Gynecology, Tokyo Medical University, Shinjuku-Ku, Tokyo 160-0023, Japan; (H.N.); (Y.S.)
| | - Yosuke Sakai
- Department of Obstetrics and Gynecology, Tokyo Medical University, Shinjuku-Ku, Tokyo 160-0023, Japan; (H.N.); (Y.S.)
| | - Hirokuni Takano
- Department of Obstetrics and Gynecology, The Jikei University Kashiwa Hospital, Kashiwa 277-8567, Japan; (H.T.); (T.S.); (K.Y.)
| | - Toshiyuki Seki
- Department of Obstetrics and Gynecology, The Jikei University Kashiwa Hospital, Kashiwa 277-8567, Japan; (H.T.); (T.S.); (K.Y.)
| | - Kota Yokosu
- Department of Obstetrics and Gynecology, The Jikei University Kashiwa Hospital, Kashiwa 277-8567, Japan; (H.T.); (T.S.); (K.Y.)
| | - Yukihiro Hirata
- Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Minato-Ku, Tokyo 105-8461, Japan;
| | - Koyo Yoshida
- Department of Obstetrics and Gynecology, Juntendo University Urayasu Hospital, Urayasu 279-0021, Japan; (K.Y.); (T.U.)
| | - Takafumi Ujihira
- Department of Obstetrics and Gynecology, Juntendo University Urayasu Hospital, Urayasu 279-0021, Japan; (K.Y.); (T.U.)
| | - Fuminori Kimura
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara 634-8522, Japan; (H.K.); (T.M.); (K.I.); (Y.Y.); (R.K.); (F.K.)
| |
Collapse
|
|
2
|
Kawahara N, Kawaguchi R, Maehana T, Yamanaka S, Yamada Y, Kobayashi H, Kimura F. The Endometriotic Neoplasm Algorithm for Risk Assessment (e-NARA) Index Sheds Light on the Discrimination of Endometriosis-Associated Ovarian Cancer from Ovarian Endometrioma. Biomedicines 2022; 10:2683. [PMID: 36359203 PMCID: PMC9687708 DOI: 10.3390/biomedicines10112683] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Revised: 09/06/2022] [Accepted: 10/21/2022] [Indexed: 11/26/2023] Open
Abstract
BACKGROUND Magnetic resonance (MR) relaxometry provides a noninvasive tool to discriminate endometriosis-associated ovarian cancer (EAOC) from ovarian endometrioma (OE) with high accuracy. However, this method has a limitation in discriminating malignancy in clinical use because the R2 value depends on the device manufacturer and repeated imaging is unrealistic. The current study aimed to reassess the diagnostic accuracy of MR relaxometry and investigate a more powerful tool to distinguish EAOC from OE. METHODS This retrospective study was conducted at our institution from December, 2012, to May, 2022. A total of 150 patients were included in this study. Patients with benign ovarian tumors (n = 108) mainly received laparoscopic surgery, and cases with suspected malignancy (n = 42) underwent laparotomy. Information from a chart review of the patients' medical records was collected. RESULTS A multiple regression analysis revealed that the age, the tumor diameter, and the R2 value were independent malignant predicting factors. The endometriotic neoplasm algorithm for risk assessment (e-NARA) index provided high accuracy (sensitivity, 85.7%; specificity, 87.0%) to discriminate EAOC from OE. CONCLUSIONS The e-NARA index is a reliable tool to assess the probability of malignant transformation of endometrioma.
Collapse
Affiliation(s)
- Naoki Kawahara
- Department of Obstetrics and Gynecology, Nara Medical University, Kashihara 634-8522, Japan
| | | | | | | | | | | | | |
Collapse
|
|
3
|
Yamanaka S, Kawahara N, Kawaguchi R, Waki K, Maehana T, Fukui Y, Miyake R, Yamada Y, Kobayashi H, Kimura F. The Comparison of Three Predictive Indexes to Discriminate Malignant Ovarian Tumors from Benign Ovarian Endometrioma: The Characteristics and Efficacy. Diagnostics (Basel) 2022; 12:diagnostics12051212. [PMID: 35626367 PMCID: PMC9140823 DOI: 10.3390/diagnostics12051212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Revised: 05/06/2022] [Accepted: 05/10/2022] [Indexed: 12/10/2022] Open
Abstract
This study aimed to evaluate the prediction efficacy of malignant transformation of ovarian endometrioma (OE) using the Copenhagen Index (CPH-I), the risk of ovarian malignancy algorithm (ROMA), and the R2 predictive index. This retrospective study was conducted at the Department of Gynecology, Nara Medical University Hospital, from January 2008 to July 2021. A total of 171 patients were included in the study. In the current study, cases were divided into three cohorts: pre-menopausal, post-menopausal, and a combined cohort. Patients with benign ovarian tumor mainly received laparoscopic surgery, and patients with suspected malignant tumors underwent laparotomy. Information from a review chart of the patients’ medical records was collected. In the combined cohort, a multivariate analysis confirmed that the ROMA index, the R2 predictive index, and tumor laterality were extracted as independent factors for predicting malignant tumors (hazard ratio (HR): 222.14, 95% confidence interval (CI): 22.27−2215.50, p < 0.001; HR: 9.80, 95% CI: 2.90−33.13, p < 0.001; HR: 0.15, 95% CI: 0.03−0.75, p = 0.021, respectively). In the pre-menopausal cohort, a multivariate analysis confirmed that the CPH index and the R2 predictive index were extracted as independent factors for predicting malignant tumors (HR: 6.45, 95% CI: 1.47−28.22, p = 0.013; HR: 31.19, 95% CI: 8.48−114.74, p < 0.001, respectively). Moreover, the R2 predictive index was only extracted as an independent factor for predicting borderline tumors (HR: 45.00, 95% CI: 7.43−272.52, p < 0.001) in the combined cohort. In pre-menopausal cases or borderline cases, the R2 predictive index is useful; while, in post-menopausal cases, the ROMA index is better than the other indexes.
Collapse
|
|
4
|
Pavlik EJ, Brekke E, Gorski J, Baldwin-Branch L, Miller R, DeSimone CP, Dietrich CS, Gallion HS, Ueland FR, van Nagell JR. Ultrasonographic Visualization of the Ovaries to Detect Ovarian Cancer According to Age, Menopausal Status and Body Type. Diagnostics (Basel) 2022; 12:diagnostics12010128. [PMID: 35054294 PMCID: PMC8775241 DOI: 10.3390/diagnostics12010128] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 12/28/2021] [Accepted: 01/03/2022] [Indexed: 11/16/2022] Open
Abstract
Because the effects of age, menopausal status, weight and body mass index (BMI) on ovarian detectability by transvaginal ultrasound (TVS) have not been established, we determined their contributions to TVS visualization of the ovaries. A total of 29,877 women that had both ovaries visualized on their first exam were followed over 202,639 prospective TVS exams. All images were reviewed by a physician. While visualization of both ovaries decreased with age, one or both ovaries could be visualized in two of every three women over 80 years of age. Around 93% of pre-menopausal women and ~69% of post-menopausal women had both ovaries visualized. Both ovaries were visualized in ~72% of women weighing over 300 lbs. and in ~70% of women with a BMI over 40. Conclusions: Age had the greatest influence on the visualization of the ovaries. The ovaries can be visualized well past the menopause. Body habitus was not limiting to TVS ovarian imaging, and TVS should be considered capable of imaging one or both ovaries in two of every three women over 80 years of age. Thus, older and obese patients remain good candidates for TVS exams.
Collapse
Affiliation(s)
- Edward J. Pavlik
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, KY 40536-0293, USA; (J.G.); (L.B.-B.); (R.M.); (C.P.D.); (C.S.D.); (H.S.G.); (F.R.U.); (J.R.v.N.J.)
- Correspondence: ; Tel.: +1-859-321-9313
| | - Emily Brekke
- Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS 66160, USA;
| | - Justin Gorski
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, KY 40536-0293, USA; (J.G.); (L.B.-B.); (R.M.); (C.P.D.); (C.S.D.); (H.S.G.); (F.R.U.); (J.R.v.N.J.)
| | - Lauren Baldwin-Branch
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, KY 40536-0293, USA; (J.G.); (L.B.-B.); (R.M.); (C.P.D.); (C.S.D.); (H.S.G.); (F.R.U.); (J.R.v.N.J.)
| | - Rachel Miller
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, KY 40536-0293, USA; (J.G.); (L.B.-B.); (R.M.); (C.P.D.); (C.S.D.); (H.S.G.); (F.R.U.); (J.R.v.N.J.)
| | - Christopher P. DeSimone
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, KY 40536-0293, USA; (J.G.); (L.B.-B.); (R.M.); (C.P.D.); (C.S.D.); (H.S.G.); (F.R.U.); (J.R.v.N.J.)
| | - Charles S. Dietrich
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, KY 40536-0293, USA; (J.G.); (L.B.-B.); (R.M.); (C.P.D.); (C.S.D.); (H.S.G.); (F.R.U.); (J.R.v.N.J.)
| | - Holly S. Gallion
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, KY 40536-0293, USA; (J.G.); (L.B.-B.); (R.M.); (C.P.D.); (C.S.D.); (H.S.G.); (F.R.U.); (J.R.v.N.J.)
| | - Frederick Rand Ueland
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, KY 40536-0293, USA; (J.G.); (L.B.-B.); (R.M.); (C.P.D.); (C.S.D.); (H.S.G.); (F.R.U.); (J.R.v.N.J.)
| | - John R. van Nagell
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, KY 40536-0293, USA; (J.G.); (L.B.-B.); (R.M.); (C.P.D.); (C.S.D.); (H.S.G.); (F.R.U.); (J.R.v.N.J.)
| |
Collapse
|